Arcus Biosciences Inc (RCUS)
Debt-to-capital ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Total stockholders’ equity | US$ in thousands | 462,000 | 520,000 | 566,000 | 600,000 | 657,000 | 699,000 | 747,000 | 797,000 | 842,000 | 542,607 | 604,555 | 664,790 | 502,000 | 544,417 | 428,710 | 140,638 | 164,000 | 177,227 | 196,646 | 221,567 |
Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2023 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $462,000K)
= 0.00
The debt-to-capital ratio of Arcus Biosciences Inc has consistently been reported as 0.00 throughout the past eight quarters. This indicates that the company has not utilized any debt financing in relation to its capital structure during this period. A debt-to-capital ratio of 0.00 suggests that the company relies solely on equity financing for its operations and growth initiatives. It may signify a conservative financial strategy aimed at minimizing financial risk and interest expenses. However, it is essential to consider other factors, such as the company's overall financial health, liquidity position, and future growth prospects, to gain a comprehensive understanding of its financial strength and stability.
Peer comparison
Dec 31, 2023